Patent Classification

Gene, Therapy/Delivery/Identification

1. Targeted cross-linked nanoparticles and their use in vivo gene delivery
    
2. Ocular gene therapy using avalanche-mediated transfection
    
3. Polymeric carrier for delivery of small interfering RNA
    
4. In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
    
5. Delivery of DNA or RNA via gap junctions from host cells to target cells and a cell-based delivery system for antisense or siRNA
    
6. Tetracycline-regulated adeno-associated viral (AAV) vectors for gene delivery to the nervous system
    
7. Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
    
8. Virus envelope vector for gene transfer
    
9. Hepatocyte growth factor gene therapy for parkinson's disease
    
10. Small interference RNA gene therapy
     
11. Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyl transferase
     
12. Methods of controlling cell differentiation and growth using a fusion protein and a drug
     
13. Methods of gene transfer to astrocytes with mokola virus pseudotyped lentivirus vectors
     
14. Enhancement of the immune response for vaccine and gene therapy applications
     
15. Mammalian tumor susceptibility gene products and their uses
     
16. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus virions
     
17. Compositions and methods for systemic nucleic acid sequence delivery
     
18. Settings for recombinant adenoviral-based vaccines
     
19. Methods and compositions for heat activated gene therapy using cytolethal distending toxin
     
20. Methods of treating lysosomal storage related diseases by gene therapy
     
21. Antibodies to M-CSF
     
22. Hirulog-like peptide and gene therapy
     
23. Gene switch systems employing regulators with decreased dimerization
     
24. Nucleic acid injected into hepatic vein lumen
     
25. Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies and gene therapy in the CNS
     
26. Photochemical internalization for virus-mediated molecule delivery into the cyosol
     
27. Gene therapy for tumors using minus-strand RNA viral vectors encoding immunostimulatory cytokines
     
28. Genetic screen for bioactive peptides
     
29. Gene regulation therapy involving ferritin
     
30. Use of targeted cross-linked nanoparticles for in vivo gene delivery
     
31. Method for introducing a biological molecule using a viral envelope and heparin and system therefore
     
32. Antibody fragment-targeted immunoliposomes for systemic gene delivery
     
33. Cancer cell targeting gene delivery method
     
34. Compounds promoting delivery of genes
     
35. Viral vectors for gene therapy
     
36. Tetracycline-regulated adeno-associated viral (AAV) vectors for gene delivery to the nervous system
     
37. AAV vectors for gene delivery to the lung
     
38. Sustained DNA delivery from structural matrices
     
39. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
     
40. In vivo production and delivery of erythropoietin or insulinotropin for gene therapy
     
41. Adenovirus serotype 30 (Ad30)
     
42. Method of delivering genes to the central nervous system of a mammal
     
43. Vectors with modified protease-dependent tropism
     
44. Use of nanoparticles for the DNA administration to a target organ
     
45. Methods for cardiac gene transfer
     
46. Systemic gene delivery vehicles for the treatment of tumors
     
47. Method of expressing foreign gene in kidney
     
48. GLP-1 gene delivery for the treatment of type 2 diabetes
     
49. Gene therapy agent for Haemophilia B and its preparation method
     
50. Tumor-specific vector for gene therapy
     
51. Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells
     
52. Methods and products for delivering biological molecules to cells using multicomponent nanostructures
     
53. Gene therapy using TGF-.beta.
     
54. Stable lipid-comprising drug delivery complexes and methods for their production
     
55. Photocleavable DNA transfer agent
     
56. Ligand activated transcriptional regulator proteins
     
57. Growth factor therapy mobilization of stem cells into the peripheral blood
     
58. Tumor radiosensitization using gene therapy
     
59. Hyperthermic inducible expression vectors for gene therapy and methods of use thereof
     
60. Mixed-cell gene therapy
     
61. Method of acquiring immunological tolerance
     
62. Self-rearranging DNA vectors
     
63. Methods for treating or preventing angiogenesis-dependent symptoms
     
64. Gene delivery compositions and methods
     
65. Gene delivery vehicle expressing the aptosis-inducing proteins VP2 and/or apoptin
     
66. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
     
67. Herpes virus strains for gene therapy
     
68. Gene therapy by small fragment homologous replacement
     
69. Devices and processes for distribution of genetic material to mammalian limb
     
70. Bovine immunodeficiency virus (BIV) based vectors
     
71. Myeloid precursor cell useful for gene therapy and for modulation of immune responses
     
72. Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof
     
73. Virus vectors and methods of making and administering the same
     
74. Nucleic acid formulations for gene delivery and methods of use
     
75. Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
     
76. Hyaluronic acid mediated adenoviral transduction
     
77. Nucleic acid injected into hapatic vein lumen and delivered to primate liver
     
78. Human monoclonal antibodies to interleukin-5
     
79. Compositions for receptor/liposome mediated transfection and methods of using same
     
80. Vesicular monoamine transporter gene therapy in parkinson's disease
     
81. Viral and non-viral vectors as vehicles for delivering transgenes for treating bone pathologies
     
82. Hyperthermic inducible expression vectors for gene therapy and methods of use thereof
     
83. Methods for enhanced retroviral-mediated gene transfer
     
84. Retroviral vectors including modified envelope escort proteins
     
85. Design principle for the construction of expression constructs for gene therapy
     
86. Defective adenoviruses and corresponding complementation lines
     
87. Use of soluble costimulatory factor for tumor immuno-gene therapy
     
88. Inducible expression vectors and methods of use thereof
     
89. Packaging systems for human recombinant adenovirus to be used in gene therapy
     
90. Stress-responsive induction of a therapeutic agent and methods of use
     
91. Mutant NURR1 gene in Parkinson's disease
     
92. Hematopoietic stem cell proliferating agents
     
93. Reversible masking of liposomal complexes for targeted delivery
     
94. Recombinant adenoviruses for gene therapy in cancers
     
95. Isolated mammalian membrane protein genes; related reagents
     
96. Use of marrow-derived glial progenitor cells as gene delivery vehicles into the central nervous system
     
97. Particles for gene therapy
     
98. Recombinant double-stranded RNA phage, and use of the same
     
99. Intravascular delivery of nucleic acid
     
100. Mixed-cell gene therapy
      
101. Compositions comprising tissue specific adenoviral vectors
      
102. Vector for reversible gene integration
      
103. Methods of preparing bone marrow stromal cells for use in gene therapy
      
104. Recombinant adenoviral vector and methods of use
      
105. Gene therapy for cardiomyopathy
      
106. Enhanced expression of transgenes
      
107. Gene therapy by administration of genetically engineered CD34⁺ cells obtained from cord blood
      
108. Vectors derived from South African Arbovirus No. 86
      
109. Gene therapy by cell specific targeting
      
110. Vector for the expression of two foreign genes
      
111. Inhibition of vascular smooth muscle cell proliferation
      
112. Circular DNA molecule with conditional origin of replication, method for preparing the same and use thereof in gene therapy
      
113. KVLQT1—a long QT syndrome gene
      
114. Methods for producing high titre vectors and compositions used in such methods
      
115. Adiponectin gene therapy
      
116. Methods and reagents for the detection of antibodies to adenovirus
      
117. AAV2 vectors and methods
      
118. Adenoviral vectors encoding an antibody fused to a CD4 extracellular domain
      
119. Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins
      
120. Compositions and methods for helper-free production of recombinant adeno-associated viruses
      
121. Vectors and methods for gene transfer
      
122. Replicating adenovirus vectors
      
123. Antitumour vector constructs and methods
      
124. Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
      
125. Gene therapy for cerebrovascular disorders
      
126. Tumour-specific vector for gene therapy
      
127. Modulation of endogenous gene expression in cells
      
128. Relationship of ABC transport proteins with hematopoietic stem cells and methods of use thereof
      
129. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
      
130. Neurogenesis inducing genes
      
131. Methods and compositions for enhancing the delivery of a nucleic acid to a cell
      
132. Virus envelope vector for gene transfer
      
133. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
      
134. Gene delivery vectors with cell type specificity for mesenchymal stem cells
      
135. Retroviral vectors, methods for their preparation and their use for gene transfer into CD4-positive cells
      
136. Gene delivery system and methods of use
      
137. Method of inducing tumor cell apoptosis using trail/Apo-2 ligand gene transfer
      
138. Polynucleotide complex delivery
      
139. Particle delivery techniques
      
140. Controlled surface-associated delivery of genes and oligonucleotides
      
141. Methods and compositions for the treatment of defects in lipoprotein metabolism
      
142. Gene therapy vehicle comprising dermal sheath tissue
      
143. Protection from ionizing irradiation or chemotherapeutic drug damage by in vivo gene therapy
      
144. Peptides derived from STEAP1
      
145. Selective precipitation of viruses
      
146. Antitumoral composition based on immunogenic polypeptide with modified cell location
      
147. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and virues
      
148. Formation of polyampholytes in the presence of a polyion
      
149. Packaging systems for human recombinant adenovirus to be used in gene therapy
      
150. Methods and compositions for efficient gene transfer using transcomplementary vectors
      
151. Monocyte-specific particulate delivery vehicle
      
152. In vitro process for selecting phage resistant to blood inactivation
      
153. Gene Therapy for proliferative vitreoretinopathy
      
154. Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction
      
155. Bovine immunodeficiency virus (BIV) based vectors
      
156. Methods of treating various cancers using melanoma differentiation associated protein
      
157. Methods and compositions for increasing the infectivity of gene transfer vectors
      
158. Gene delivery compositions and methods
      
159. Tumor targeted vector
      
160. Reverse gene therapy
      
161. Combination therapy using nucleic acids and radio therapy
      
162. Immunomodulation by genetic modification of dendritic cells and B cells
      
163. Site specific recombinase based method for producing adenoviral vectors
      
164. Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
      
165. In vitro construction of SV40 viruses and pseudoviruses
      
166. Delivery of therapeutic gene products by intestinal cell expression
      
167. Method of observing vasculogenesis in vitro using cultured allantois
      
168. Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
      
169. Replication incompetent herpes viruses for use in gene therapy
      
170. Vectors and methods for immunization or therapeutic protocols
      
171. Cardiac-cell specific enhancer elements and uses thereof
      
172. Retroviral delivery system
      
173. Methods for encapsulating plasmids in lipid bilayers
      
174. Synthetic transfection vectors
      
175. Method for the identification of a receptor
      
176. Methods for the administration of adenovirus p53
      
177. Methods for compositions for in vivo gene delivery
      
178. Gene delivery vectors with cell type specificity for primary human chondrocytes
      
179. High efficiency transfection based on low electric field strength, long pulse length
      
180. Lentiviral-mediated growth factor gene therapy for neurodegenerative diseases
      
181. Recombinant adenoviruses expressing interleukin-18 protein and gene therapy using them
      
182. Gene therapy using TGF-.beta
      
183. Retrovirus vectors derived from avian sarcoma leukosis viruses permitting transfer of genes into mammalian cells and therapeutic uses thereof
      
184. Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction
      
185. Gene therapy method for reducing risk of atherosclerosis
      
186. Antibiotic inducible/repressible genetic construct for gene therapy or gene immunization
      
187. Mammalian genes involved in viral infection and tumor suppression
      
188. Encapsulated cells producing viral particles
      
189. Folypolyglutamyl synthetase gene transfer to enhance antifolate
      
190. Method for the quantitation of alphavirus replicon particles
      
191. Herpes simplex virus expressing foreign genes and method for treating cancers therewith
      
192. Method for targeted delivery of nucleic acids
      
193. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
      
194. Recombinant adeno viruses comprising an inserted gene encoding apolipoprotein and their use in gene therapy for dyslipoproteinemias
      
195. Vectors including foreign genes and negative selective markers
      
196. Cancer gene therapy based on translational control of a suicide gene
      
197. Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system particularly in brain
      
198. DNA molecules encoding hormone-dependent forms of the adeno-associated virus rep proteins
      
199. Targeted liposome gene delivery
      
200. Compositions and methods for elimination of unwanted cells
      
201. Paramyxovirus vectors used for transfer of foreign genes
      
202. Therapy for cellular accumulation in chronic inflammatory diseases
      
203. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
      
204. Method of making microencapsulated DNA for vaccination and gene therapy
      
205. Viral recombinant vectors for expression in muscle cells
      
206. Recombinant adenovirus
      
207. SOX-9 gene and protein and use in the regeneration of bone or cartilage
      
208. Methods for regulating gene expression using light
      
209. Methods for encapsulating nucleic acids in lipid bilayers
      
210. Combination immunogene therapy
      
211. Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders
      
212. Vectors that repress heterologous promoter activity
      
213. Gene-entrapped liposomes preparation and process for the preparation thereof
      
214. Use of lithium (Li+) for the preparation of a composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy
      
215. Mutant herpes simplex viruses and uses thereof
      
216. Genes identified as required for proliferation in Escherichia coli
      
217. Transfer method for specific cellular localization of nucleic acids
      
218. Artificial chromosome
      
219. Treatment of pancreatic adenocarcinoma by cytotoxic gene therapy
      
220. Encapsulated cells containing an amplified expression vector as a drug delivery device
      
221. Hyperthermic inducible expression vectors for gene therapy and methods of use thereof
      
222. Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies and gene therapy in the CNS
      
223. Method of producing infectious reovirus
      
224. Treatment of ocular neovascularization and related diseases
      
225. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
      
226. Packaging systems for human recombinant adenovirus to be used in gene therapy
      
227. Controlling immune response to specific antigens
      
228. Vectors for the diagnosis and treatment of solid tumors including melanoma
      
229. Recognition of tumor-specific gene products in cancer
      
230. Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same
      
231. Human gene relating to respiratory diseases and obesity
      
232. Mini-E1A gene and gene products
      
233. Triple hybrid amplicon vector systems to generate retroviral packaging lines
      
234. Method for gene therapy using nucleic acid loaded polymeric microparticles
      
235. Herpes simplex virus amplicon vector targeting system and method of using same
      
236. Method of diagnosing ischemic stroke via UCP-2 detection
      
237. Methods for enhanced virus-mediated DNA transfer using molecules with virus-and cell-binding domains
      
238. Identification of the gene causing the mouse scurfy phenotype and its human ortholog
      
239. Microencapsulated DNA for vaccination and gene therapy
      
240. Pancreatic cancer genes
      
241. Use of trans-activation and CIS-activation to increase the persistence of a transgene in an at least E4-deficient adenovirus
      
242. Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
      
243. Glucocorticoid enhancement of gene expression
      
244. Targeting adenovirus with use of constrained peptide motifs
      
245. Somatic cell gene therapy
      
246. Herpes virus vectors for dendritic cells
      
247. Tissue-vectors specific replication and gene expression
      
248. Targeted vectors
      
249. Adenoviral-vector-mediated gene transfer into medullary motor neurons
      
250. Gene therapy for obesity
      
251. Single-chain insulin analog and a polynucleotide sequence encoding the analog
      
252. Methods and compositions for in vivo gene therapy
      
253. Temperature-sensitive regulation of viral vector production
      
254. Materials and methods for intracellular delivery of biologically active molecules
      
255. Method for nucleic acid transfection of cells
      
256. Polymeric gene delivery system
      
257. Methods of in vivo gene transfer using a sleeping beauty transposon system
      
258. HSV viral vector
      
259. Transfer and expression of gene sequences into nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
      
260. Methods and compositions for treatment of diabetes and related conditions via gene therapy
      
261. Trans-somatics with gene transfer into mammary epithelial cells
      
262. Adenoviral vectors with tandem fiber proteins
      
263. Modulating transcription of genes in vascular cells
      
264. Methods of administering adenoviral vectors
      
265. Mutant having uracil phosphoribosyl transferase activity
      
266. Metabolically activated recombinant viral vectors and methods for the preparation and use
      
267. Cell-based gene therapy
      
268. Recombinant yellow fever virus and method of use thereof
      
269. Agent for gene therapy of dilated cardiomyopathy
      
270. Mutants of the Rb and p53 genes and uses thereof
      
271. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
      
272. Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier
      
273. System for the in vivo delivery and expression of heterologous genes in the bone marrow
      
274. Medical use of gene and vector encoding a multisubstrate deoxyribonucleoside kinase
      
275. Lipoxygenase proteins and polynucleotides encoding the same
      
276. Lymphoma-susceptible transgenic mice and methods for studying drug sensitivity of lymphomas
      
277. Adenovirus-mediated gene therapy
      
278. Hybrid vectors for gene therapy
      
279. Chimeric viral packaging signal without gag gene sequences
      
280. Genetic constructs for delaying or repressing the expression of a target gene
      
281. Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene
      
282. Identification of a G protein-coupled receptor transcriptionally regulated by protein tyrosine kinase signaling in hematopoietic cell
      
283. Method for gene transfer to the central nervous system
      
284. Cell-based drug screens for regulators of gene expression
      
285. NK-1 receptor antagonists for prevention of neurogenic inflammation in gene therapy
      
286. Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
      
287. Microencapsulation and sustained release of oligonucleotides
      
288. Complex of biotinylated viral vector and ligand for targeted gene delivery
      
289. Method of stable integration of DNA into neurons
      
290. Tumor radiosensitization using gene therapy
      
291. Muscle reinnervation and motor axon sprouting by administering DNA sequences encoding NT-3 and CNTF
      
292. Retroviral gene transfer vectors
      
293. Retroviral gene therapy vectors and therapeutic methods based thereon
      
294. Methods and reagents for facilitating transcription
      
295. Therapeutic Gene
      
296. Adenoviral helper vectors
      
297. Vaccina virus comprising cytokine and/or tumor associated antigen genes
      
298. CaESS1: a Candida albicans gene, methods for making and using, and targeting it and its expression products for antifungal applications
      
299. Concurrent flow mixing methods and apparatuses for the preparation of gene therapy vectors and compositions prepared thereby
      
300. Compositions and methods for wound healing
      
301. Protected one-vial formulation for nucleic acid molecules, methods of making the same by in-line mixing, and related products and methods
      
302. Methods for encapsulating plasmids in lipid bilayers
      
303. In vivo production and delivery of insulinotropin for gene therapy
      
304. Adenoviral vectors encoding a cytokine and a conditionally lethal gene
      
305. Invasive bacterial vectors for expressing alphavirus replicons
      
306. Gene therapy for the treatment of solid tumors using recombinant adeno-associated virus vectors
      
307. Use of G-actin for improving transfection of a polynucleotide into a cell
      
308. Method of suppressing tumor cell growth by administering a decorin gene or gene product
      
309. Preparation of recombinant adenovirus carrying a rep gene of adeno-associated virus
      
310. Gene construct and its use
      
311. Lentivirus-based gene transfer vectors
      
312. Enzyme combinations for destroying proliferative cells
      
313. Formulated nucleic acid compositions and methods of administering the same for gene therapy
      
314. Vesicular monoamine transporter gene therapy in Parkinson's disease
      
315. Viral vector complexes having adapters of predefined valence
      
316. Method of plasmid DNA production and purification
      
317. Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (LAG-3)
      
318. Adeno-associated virus capsid immunologic determinants
      
319. Complex of DNA and microparticle of defatted lipid-binding protein for gene therapy
      
320. In vitro sorting method
      
321. Retroviral packaging cassettes amplified in the cytoplasm by autocatalytic Togavirus vectors
      
322. Method of intranasal gene transfer for protection against respiratory infection
      
323. Gene treatment to enhance feed efficiency and growth rate of livestock
      
324. Cell-based gene therapy for the pulmonary system
      
325. Methods to inhibit or enhance the binding of viral DNA to genomic host DNA
      
326. Development of viruses resistant to inactivation by the human complement system
      
327. Polymeric gene delivery
      
328. Gene-containing compositions
      
329. Expression of cloned genes in the lung by aerosol and liposome-based delivery
      
330. Transgene expression in polarized cells
      
331. Materials and methods for gene therapy
      
332. Production of chimeric antibodies with specificity to human tumor antigens
      
333. Purging leukemia cells from hematopoietic stem cells
      
334. Assays for promoter operability in central nervous system cells
      
335. Bovine cells expressing adenovirus essential functions for propagation of recombinant adenoviral vectors
      
336. Pituitary-tumor-transforming-genes, and related products
      
337. DNA molecules encoding single strand gap response proteins involved in activation of a DNA repair/cell cycle checkpoint pathway
      
338. Design principle for construction of expression constructs for gene therapy
      
339. Regulated expression of recombinant proteins using RNA viruses
      
340. Methods of administering adenoviral vectors
      
341. Delivery system for gene therapy to the brain
      
342. Adenovirus-medicated gene transfer to cardiac and vascular smooth muscle
      
343. Method of enhancing the effectiveness of DCK phosphorylated molecules
      
344. Method for the augmentation of gene expression
      
345. Zymogen activation system
      
346. Virus-like particles useful as a vector for delivering nucleic acid
      
347. Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery
      
348. Methods and reagents for inhibiting proliferation of smooth muscle cells
      
349. Sensitizing cells to compounds using lipid-mediated gene and compound delivery
     
     
350. Targeted gene delivery system
     
     
351. In Utero treatment of CFTR-related deficiencies
     
     
352. Recombinant adenoviral vectors comprising a splicing sequence 
     
     
353. Gene transfer in chickens by introduction of DNA into muscle in ovo
     
     
354. Uteroglobin gene therapy for epithelial cell cancer
     
     
355. Cationic peptides, Cys-Trp-(Lys)n, for gene delivery
     
     
356. Intravascular delivery of non-viral nucleic acid
     
     
357. Gene delivery compositions and methods
     
     
358. Proteins related to encapsulation and genes encoding the same
     
     
359. Non-invasive gene targeting to the brain
     
     
360. Transgene expression systems
     
     
361. Use of a melanoma differentiation associated gene (mda-7) for inducing apoptosis of a tumor cell
     
     
362. Methods for using the obese gene and its gene product to stimulate hematopoietic development
     
     
363. Transcriptional inhibitor
     
     
364. Gene therapy for pulmonary edema using adenovirus vectors encoding Na,K-ATPase
     
     
365. Transposition assembly for gene transfer in eukaryotes
     
     
366. Method for preparing a viral aerosol and its use in gene therapy treatment
     
     
367. Method for detection and treatment of breast cancer 
     
     
368. Radiation enhanced gene therapy for tumors expressing a gene for a viral pyrimidine kinase in the presence of a 5'-halogenated pyrimidine 
     
     
369. Lipid vesicles containing adeno-associated virus rep protein for transgene integration and gene therapy 
     
     
370. Integrative protein-DNA cochleate formulations and methods for transforming cells
      
     
371. Episomal expression vector for human gene therapy
      
     
372. Vectors and methods for immunization or therapeutic protocols
      
     
373. Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety
      
     
374. Gene therapy in coronary angioplasty and bypass
      
     
375. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus virions to treat lysosomal storage disease
      
     
376. Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof
      
     
377. Method for treatment in gene therapy and use of guanine derivative therefor
      
     
378. Methods for use of Mpl ligands with primitive human stem cells
      
     
379. Minimally invasive gene therapy delivery and method
      
     
380. Coxsackie virus vectors for delivery of nucleic acids encoding antigenic or therapeutic products
      
     
381. Method of enhancing the delivery of nucleic acids using silica nanoparticles
      
     
382. Bovine adenovirus type 3 genome and vector systems derived therefrom
      
     
383. Induction of angiogenesis in heart muscle by a DNA sequence encoding an angiogenic protein
      
     
384. Delivery of nucleic acid materials
      
     
385. Gene therapy for congestive heart failure
      
     
386. Genetically engineered retroviral vector particles capable of infecting non-dividing cells
      
     
387. Compositions and methods for nucleic acid delivery to the lung
      
     
388. Adenovirus-medicated gene transfer to cardiac and vascular smooth muscle
      
     
389. Defective packaging non-oncoviral vectors based on HIV
      
     
390. Intracellular delivery vehicles
      
     
391. Gene transfer method with the use of serum-free medium
      
     
392. Method for enhancing myoblast migration and invasion in the context of gene therapy
      
     
393. Method for generating dopaminergic cells derived from neural precursors
      
     
394. Immunomodulation by genetic modification of dendritic cells and B cells
      
     
395. Use of a non-mammalian DNA virus to express an exogenous gene in a mammalian cell
      
     
396. Isolated mammalian membrane protein genes; related reagents
      
     
397. Method of making microencapsulated DNA for vaccination and gene therapy
      
     
398. Sonic nebulized nucleic acid/cationic liposome complexes and methods for pulmonary gene delivery
      
     
399. Packaging systems for human recombinant adenovirus to be used in gene therapy
      
     
400. Polymeric gene delivery system
      
     
401. Combination product for enhanced gene delivery comprising a hyaluronidase
      
     
402. Gene delivery by secretory gland expression
      
     
403. Method for gene therapy using nucleic acid loaded polymeric microparticles
      
     
404. Medicament comprising HGF gene
      
     
405. Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction
      
     
406. Method for treating brain cancer with a conditionally lethal gene
      
     
407. Gene therapy for regulating bladder smooth muscle tone
      
     
408. Transgenomic viruses
      
     
409. Method and devices for creating a trap for confining therapeutic drugs and/or genes in the myocardium
      
     
410. Protection of the esophagus from chemotherapeutic or irradiation damage by gene therapy
      
     
411. Gene therapy for solid tumors, papillomas and warts
      
     
412. Polyester analogue of poly-L-lysine as a soluble, biodegradable gene delivery carrier
      
     
413. Biodegradable mixed polymeric micelles for gene delivery
      
     
414. Gene expression in mammalian cells
      
     
415. Ocular gene therapy
      
     
416. Somatic gene therapy to suppress secondary cataract formation following eye surgery
      
     
417. Genetic induction of anti-viral immune response and genetic vaccine for filovirus
      
     
418. Compositions and methods for delivery of genetic material
      
     
419. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy and protein production
      
     
420. Gene therapies for enhancing cardiac function
      
     
421. Gene transfer for studying and treating a connective tissue of a mammalian host
      
     
422. Delivery of polypeptide-encoding plasmid DNA into the cytosol of macrophages by attenuated listeria suicide bacteria
      
     
423. Cell-specific molecule and method for importing DNA into a nucleus
      
     
424. Materials and methods for delivery and expression of heterologous DNA in vertebrate cells
      
425. Oral delivery of adeno-associated viral vectors
      
     
426. Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method
      
     
427. Gene therapies for enhancing cardiac function
      
     
428. Liposome-mediated transfection of central nervous system cells
      
     
429. Gene therapy for cystic fibrosis
      
     
430. Methods and compositions for use in gene therapy for treatment of hemophilia
      
     
431. Method for gene therapy involving suppression of an immune response
      
     
432. Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
      
     
433. Receptor ligand-facilitated delivery of biologically active molecules
      
     
434. DNA molecule encoding for cellular uptake of Mycobacterium tuberculosis and uses thereof
      
     
435. Targeted delivery of genes encoding interferon
      
     
436. Gene-containing compositions
      
     
437. Tissue-specific enhancer active in prostate
      
     
438. In vivo production and delivery of erythropoietin for gene therapy
      
     
439. Microsphere encapsulation of gene transfer vectors
      
     
440. Method for importing biologically active molecules into cells
      
     
441. Formulated nucleic acid compositions and methods of administering the same for gene therapy
      
     
442. Formulated nucleic acid compositions and methods of administering the same for gene therapy
      
     
443. Cationic lipids for gene therapy
      
     
444. Packaging systems for human recombinant adenovirus to be used in gene therapy (*Large document -- long loading time)
      
     
445. Gene up-regulated in regenerating liver
      
     
446. Device and method for encapsulated gene therapy
      
     
447. Formulations for non-viral in vivo transfection in the lungs
      
     
448. Surface expression of enzyme in gene directed prodrug therapy
      
     
449. Solid microparticles for gene delivery
      
     
450. Modified protein for gene transfer and process for producing the same